2006_AGEN_10K_full.pdf page 50
author: ayildiz
duplicates:http://www.antigenics.com/investors/sec/10k/2006_AGEN_10-K.pdf
Millennium | Clinicians | Oncology | VELCADE | Reimbursement Overview VELCADE ® Campath ® Research and Development Clinical Trials Resources for Patients MECHANISM PHASE 3 TRIAL DESIGN PHASE 3 TRIAL RESULTS ONLY 1 PRIOR THERAPY PHASE 2 TRIAL DESIGN AND RESULTS SAFETY PROFILE - Thrombocytopenia - Peripheral Neuropathy DOSING SCHEDULE DOSE-MODIFICATION ELINES HANDLING AND ADMINISTRATION PRESCRIBING CONSIDERATIONS REIMBURSEMENT...
Millennium | Clinicians | Oncology | VELCADE | Dose Modification Overview VELCADE ® Campath ® Research and Development Clinical Trials Resources for Patients MECHANISM PHASE 3 TRIAL DESIGN PHASE 3 TRIAL RESULTS ONLY 1 PRIOR THERAPY PHASE 2 TRIAL DESIGN AND RESULTS SAFETY PROFILE - Thrombocytopenia - Peripheral Neuropathy DOSING SCHEDULE DOSE-MODIFICATION ELINES HANDLING AND ADMINISTRATION PRESCRIBING CONSIDERATIONS REIMBURSEMENT...
Millennium | Clinicians | Oncology | VELCADE | Maintenance Overview VELCADE ® Campath ® Research and Development Clinical Trials Resources for Patients MECHANISM PHASE 3 TRIAL DESIGN PHASE 3 TRIAL RESULTS ONLY 1 PRIOR THERAPY PHASE 2 TRIAL DESIGN AND RESULTS SAFETY PROFILE - Thrombocytopenia - Peripheral Neuropathy DOSING SCHEDULE DOSE-MODIFICATION ELINES HANDLING AND ADMINISTRATION PRESCRIBING CONSIDERATIONS REIMBURSEMENT...
Millennium | Clinicians | Oncology | VELCADE | Safety: Peripheral Neurophathy Overview VELCADE ® Campath ® Research and Development Clinical Trials Resources for Patients MECHANISM PHASE 3 TRIAL DESIGN PHASE 3 TRIAL RESULTS ONLY 1 PRIOR THERAPY PHASE 2 TRIAL DESIGN AND RESULTS SAFETY PROFILE - Thrombocytopenia - Peripheral Neuropathy DOSING SCHEDULE DOSE-MODIFICATION ELINES HANDLING AND ADMINISTRATION PRESCRIBING CONSIDERATIONS REIMBURSEMENT...
Millennium | Clinicians | Oncology | VELCADE | Safety: Thrombocytopenia Overview VELCADE ® Campath ® Research and Development Clinical Trials Resources for Patients MECHANISM PHASE 3 TRIAL DESIGN PHASE 3 TRIAL RESULTS ONLY 1 PRIOR THERAPY PHASE 2 TRIAL DESIGN AND RESULTS SAFETY PROFILE - Thrombocytopenia - Peripheral Neuropathy DOSING SCHEDULE DOSE-MODIFICATION ELINES HANDLING AND ADMINISTRATION PRESCRIBING CONSIDERATIONS REIMBURSEMENT...
Millennium | Clinicians | Oncology | VELCADE | Patient Subset: Second-line Treatment Overview VELCADE ® Campath ® Research and Development Clinical Trials Resources for Patients MECHANISM PHASE 3 TRIAL DESIGN PHASE 3 TRIAL RESULTS ONLY 1 PRIOR THERAPY PHASE 2 TRIAL DESIGN AND RESULTS SAFETY PROFILE - Thrombocytopenia - Peripheral Neuropathy DOSING SCHEDULE DOSE-MODIFICATION ELINES HANDLING AND ADMINISTRATION PRESCRIBING CONSIDERATIONS REIMBURSEMENT...
Millennium | Clinicians | Oncology | VELCADE | Phase 3 Trial Results: Response and Survival – Median follow-up was limited to 8.3 months All dexamethasone patients were permitted to receive VELCADE ® (bortezomib) for Injection after interim analysis.VELCADE Survival advantage maintained despite at least 44% of dexamethasone patients crossing over to VELCADE prior to early...
Millennium | Clinicians | Oncology | VELCADE | Phase 3 Trial Design: APEX Overview VELCADE ® Campath ® Research and Development Clinical Trials Resources for Patients MECHANISM PHASE 3 TRIAL DESIGN PHASE 3 TRIAL RESULTS ONLY 1 PRIOR THERAPY PHASE 2 TRIAL DESIGN AND RESULTS SAFETY PROFILE - Thrombocytopenia - Peripheral Neuropathy DOSING SCHEDULE DOSE-MODIFICATION ELINES HANDLING AND ADMINISTRATION PRESCRIBING CONSIDERATIONS REIMBURSEMENT...
Millennium | Research and Development | Printable Pipeline The following is a summary of all of our potential new drugs that are currently in, or close to entering, clinical development.VELCADE ® (bortezomib) for Injection.
Millennium | Research and Development | Clinical Trials Registry and Results ETHICAL, CLINICAL AND SCIENTIFIC GOOD INTENTIONS As we develop important new medicines to treat diseases like cancer, cardiovascular diseases and inflammation, Millennium seeks to continuously demonstrate our ethical, clinical and scientific good intentions to the public.
Millennium | Top 10 Med Ad News A “Top 10” Liftoff!VELCADE ® (bortezomib) for Injection as having one of the 10 top launches in terms of first full year of sales!
Millennium | Clinicians | Oncology | VELCADE | References Overview VELCADE ® Campath ® Research and Development Clinical Trials Resources for Patients MECHANISM PHASE 3 TRIAL DESIGN PHASE 3 TRIAL RESULTS ONLY 1 PRIOR THERAPY PHASE 2 TRIAL DESIGN AND RESULTS SAFETY PROFILE - Thrombocytopenia - Peripheral Neuropathy DOSING SCHEDULE DOSE-MODIFICATION ELINES HANDLING AND ADMINISTRATION PRESCRIBING CONSIDERATIONS REIMBURSEMENT...
Millennium | Clinicians | Oncology | VELCADE | Downloads Overview VELCADE ® Campath ® Research and Development Clinical Trials Resources for Patients MECHANISM PHASE 3 TRIAL DESIGN PHASE 3 TRIAL RESULTS ONLY 1 PRIOR THERAPY PHASE 2 TRIAL DESIGN AND RESULTS SAFETY PROFILE - Thrombocytopenia - Peripheral Neuropathy DOSING SCHEDULE DOSE-MODIFICATION ELINES HANDLING AND ADMINISTRATION PRESCRIBING CONSIDERATIONS REIMBURSEMENT...
Millennium | Clinicians | Oncology | VELCADE | Cautions Overview VELCADE ® Campath ® Research and Development Clinical Trials Resources for Patients MECHANISM PHASE 3 TRIAL DESIGN PHASE 3 TRIAL RESULTS ONLY 1 PRIOR THERAPY PHASE 2 TRIAL DESIGN AND RESULTS SAFETY PROFILE - Thrombocytopenia - Peripheral Neuropathy DOSING SCHEDULE DOSE-MODIFICATION ELINES HANDLING AND ADMINISTRATION PRESCRIBING CONSIDERATIONS REIMBURSEMENT...
Millennium | Clinicians | Oncology | VELCADE | Side Effect Management Overview VELCADE ® Campath ® Research and Development Clinical Trials Resources for Patients MECHANISM DOSING CLINICAL TRIALS RESPONSES & DURATION ADDITIONAL RESPONSE DATA SAFETY PROFILE SIDE EFFECT MANAGEMENT PRESCRIBING INFORMATION MORE INFORMATION REFERENCES MANAGING THE SIDE EFFECTS OF VELCADE ® (bortezomib) FOR INJECTION Please Note: Our website...
Millennium | Clinicians | Oncology | VELCADE | Safety Profile Overview VELCADE ® Campath ® Research and Development Clinical Trials Resources for Patients MECHANISM PHASE 3 TRIAL DESIGN PHASE 3 TRIAL RESULTS ONLY 1 PRIOR THERAPY PHASE 2 TRIAL DESIGN AND RESULTS SAFETY PROFILE - Thrombocytopenia - Peripheral Neuropathy DOSING SCHEDULE DOSE-MODIFICATION ELINES HANDLING AND ADMINISTRATION PRESCRIBING CONSIDERATIONS REIMBURSEMENT...
Millennium | Clinicians | Oncology | VELCADE | Duration Overview VELCADE ® Campath ® Research and Development Clinical Trials Resources for Patients MECHANISM PHASE 3 TRIAL DESIGN PHASE 3 TRIAL RESULTS ONLY 1 PRIOR THERAPY PHASE 2 TRIAL DESIGN AND RESULTS SAFETY PROFILE - Thrombocytopenia - Peripheral Neuropathy DOSING SCHEDULE DOSE-MODIFICATION ELINES HANDLING AND ADMINISTRATION PRESCRIBING CONSIDERATIONS REIMBURSEMENT...
Millennium | Clinicians | Oncology | VELCADE | Responses Overview VELCADE ® Campath ® Research and Development Clinical Trials Resources for Patients MECHANISM PHASE 3 TRIAL DESIGN PHASE 3 TRIAL RESULTS ONLY 1 PRIOR THERAPY PHASE 2 TRIAL DESIGN AND RESULTS SAFETY PROFILE - Thrombocytopenia - Peripheral Neuropathy DOSING SCHEDULE DOSE-MODIFICATION ELINES HANDLING AND ADMINISTRATION PRESCRIBING CONSIDERATIONS REIMBURSEMENT...
Millennium | Clinicians | Oncology | VELCADE | Trials Overview VELCADE ® Campath ® Research and Development Clinical Trials Resources for Patients MECHANISM PHASE 3 TRIAL DESIGN PHASE 3 TRIAL RESULTS ONLY 1 PRIOR THERAPY PHASE 2 TRIAL DESIGN AND RESULTS SAFETY PROFILE - Thrombocytopenia - Peripheral Neuropathy DOSING SCHEDULE DOSE-MODIFICATION ELINES HANDLING AND ADMINISTRATION PRESCRIBING CONSIDERATIONS REIMBURSEMENT...
Millennium | Clinicians | Oncology | VELCADE | Dosing Overview VELCADE ® Campath ® Research and Development Clinical Trials Resources for Patients MECHANISM PHASE 3 TRIAL DESIGN PHASE 3 TRIAL RESULTS ONLY 1 PRIOR THERAPY PHASE 2 TRIAL DESIGN AND RESULTS SAFETY PROFILE - Thrombocytopenia - Peripheral Neuropathy DOSING SCHEDULE DOSE-MODIFICATION ELINES HANDLING AND ADMINISTRATION PRESCRIBING CONSIDERATIONS REIMBURSEMENT...
Millennium | Clinicians | Oncology | VELCADE | Mechanism Overview VELCADE ® Campath ® Research and Development Clinical Trials Resources for Patients MECHANISM PHASE 3 TRIAL DESIGN PHASE 3 TRIAL RESULTS ONLY 1 PRIOR THERAPY PHASE 2 TRIAL DESIGN AND RESULTS SAFETY PROFILE - Thrombocytopenia - Peripheral Neuropathy DOSING SCHEDULE DOSE-MODIFICATION ELINES HANDLING AND ADMINISTRATION PRESCRIBING CONSIDERATIONS REIMBURSEMENT...
Millennium | Media | Press Releases | 2003 | 2003-08-22 2003 2002 Millennium Announces Changes in R&D Management Cambridge, Mass., August 22, 2003 - Millennium Pharmaceuticals, Inc.
Millennium | Media | Press Releases | 2003 | 2003-09-26 2003 2002 Millennium Announces Assignment of Medicare Code For Velcade™ (bortezomib) for Injection – Received five months following launch – Cambridge, Mass., September 26, 2003 - Millennium Pharmaceuticals, Inc.
Millennium | Media | Press Releases | 2003 | 2003-10-15 This product revenue increase coupled with potential for further reduced R&D expenses from our restructuring gives us confidence that we will beat our original pro forma net loss guidance given in January 2003 and our GAAP net loss guidance provided in July 2003." COMPANY HIGHLIGHTS VELCADE™ (bortezomib) for Injection: As a result of the achievement of the target...
